Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Petscript Inc violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

What happens after a Form 483 is issued?

The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.

September 18, 2025 FDA Form 483 for Petscript Inc

Here's the summary: FDA inspected Petscript Inc in Texas and issued a Form 483 listing 22 inspectional observations following an inspection that concluded 2025-09-18. FDA records classify Petscript Inc as a producer of sterile and non sterile drug products. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Petscript Inc
FEI / inspection ID	3010282564
Inspection end date	September 18, 2025
Citation count	22

Citations explained

Observation 1 — The responsibilities and procedures applicable to the quality control unit are not

The responsibilities and procedures applicable to the quality control unit are not in writing and fully fol lowed. Specifically, a) Your firm has no written procedures outlining the responsibilities of the Quality Unit, including release or rejection of finished drug products. b) Written procedures are not review and approved and have not been assigned effective dates. c) Your firm placed an incorrect Beyond Use Da te (BUD) on th e label for Lot #25070112 of Estradiol Cypionate 2mg/1 ml Injection. The product was made on 07/07/2025 and the BUD placed on the label was 01 /31/2025. d) Media fi l ls performed by your firm with each of the technicians that work in the ISO f area do not closely simulate actual production conditions or cover worst case or mo~t challeng in g conditions. Please refer to

Observation 2 — for details

for details. e) Your firm's sterilization cycles used to render sterile drug prod ucts sterile via 1 <b><"'7, 4 c b fff) I and/or (bl( J have not been va lidated. Please refer to

Observation 3 — for details

for details. f) Your firm has not validated the cleani ng , sterilization and/or I 4 (bf< J Jprocess for the stoppers, vials and ointment tubes us ed by your firm to package sterile drug EMP!_OYEE(S) SIGNATURE DATE ISSUED SEE REVERSE Margaret M Annes, cso 9/ 1 8/2025 OF THIS PAGE Katherine M Breed, Veterinary Medical M~WArr..15 cao Officer ~By;M~W....--:s-6 X ~~~8-2n25 1111:B:1 1 PAGE I of 15 PAGES

Observation 4 — for detai ls

for detai ls. g) Your firm is not performing environmental or personnel monitoring in the classified areas (ISO ~b/ISO ~b/ISO t ) r (6J (()7 that sterile drugs products are produced . Your firm is not pert4orm in~ envfronmental monitoring during media fills. Please refer to

Observation 5 — for details

for details. h) Y ou r fi rm failed to re place a l ea ki ng HEPA fi lt er wh en fi rst ad vi se d of issue and then fa il ed to perfo rm an investigati on and p ro duct impact assessment. Please refer to

Observation 6 — for details

for details. i) Your firm does not conduct routine testing for sterility as applicable, endotoxin as applicable, or potency (assay) for all drug products produced by yo ur firm (ste ri le and non-sterile). Please re fer to OBSERVATIONS 8 & 13 for details . j) Your firm does not have an established stability testing program to justify th e Be yond Use Da tes (BUD) placed on your d ru g products (ste ril e and non -s terile). Please refer to

Observation 7 — for details

for details.

Observation 8 — Proced ures designed to prevent microbiolog ica l contamination of drug products

Proced ures designed to prevent microbiolog ica l contamination of drug products purporting to be sterile did not include validation of the aseptic and steril ization process. Specifi cal ly, a) Media fills performed by your firm with each of the technicians that work in the ISO ~ area do not closely simulate actual production conditions or cover worst case or mos4f EMPI.OYEE(S) SIGNATURE DATE ISSUED SEE REVERSE Margaret M Annes , cso 9/ 1 8/2025 OF THIS PAGE Ka t herine M Breed , Veterinary Medical M~WArr..15 cao Officer ~By;M~W....--:s-6 X ~~~8-2n25 1111:B:1 1 INS PAGE 2 of 15 PAGES

Observation 9 — Procedures designed to prevent microbiological contam in ation of drug products purporting

Procedures designed to prevent microbiological contam in ation of drug products purporting to be sterile are not. Specifically, a) Your firm has no written procedure for how to perform l !bT<4 > I testing including specifications for pass/fail of the test. Your firm is not documenting perform in g r {b)(4) 1 testi ng of <b><4 > used to make sterile drug products. b) Stoppers and (bfl4) caps are removed from an I 1bfl4) Jand placed directly onto the surface of the LFR w en fil ling. The technician then places tne stopper onto the vial using their gloved hand. When filling ster il e drug products into dropper bottles the tips and caps are also manually placed onto the dropper bottle by the technici an us in g their gloved hand. c) On 09 /12/2025 I watched the filling of lot #25090389 of Tacrolimus 0.02% Ophthalmic Solution. There were L <t>mJ of stoppers and >n.. , caps propped up.

Observation 10 — Aseptic process in g areas are deficient regarding the system for monitoring

Aseptic process in g areas are deficient regarding the system for monitoring environmental conditions. Specifically, EMPI.OYEE(S) SIGNATURE DATE ISSUED SEE REVERSE Margaret M Annes, cso 9/ 1 8/2025 OF THIS PAGE Katherine M Breed, Veterinary Medical M~WArr..15 cao Officer ~By;M~W....--:s-6 ~~~8-2n25 X 1111:3':'l t PAGE 5 of 15 PAGES

Observation 11 — Cloth i ng of personnel engaged in the ma nufacturing, processing

Cloth i ng of personnel engaged in the ma nufacturing, processing , packing and holding of drug products is not approp ri ate for the duties they perform. Specifically, gowning for personnel working in the ISO ~b /ISO t class ifi ed areas consists of the following: scrubs worn from home, a disposable sterile 'field gow n that ties in the back, a single non-sterile ha ir net, non-sterile face mask, and non-sterile shoe covers. A si ngle pa ir of ste ri le gloves are donned af te r the technician has donned the other gowni ng materials. The general gowning requ irements leave exposed skin around th e eyes, forehead and neck of the person prepari ng steri le drug products. Go wning in th e ISO prep area consists of scrubs worn f rom home , shoe covers and gloves. There is no req uirerfient for a hair net or any other protective clothi ng while preparing/mixing.

Observation 12 — There is a fa il ure to thoroughly review any unexpla in

There is a fa il ure to thoroughly review any unexpla in ed discrepancy whether or no t the batch has been al ready distributed . Specifically, during the certification of th e cleanrooms on 09/05/2024 and 03/07/2025, one of the HEPA filters in 4 <bll ) Room ~b (ISO ~b) needed attention due to leaks detected. The report does not note the size of thec4 1eaks .14 The HEPA filter was not replaced until after t he 03/07/2025 certification , whi ch was not documented. Your firm did not re-certify th e room after the replacement of the HEPA filter until 09/04/2025. Your firm did not perform an investigation into th e leaking HEPA filter or perform a product im pact assessment. Your firm does not maintain a log of all lots made in each of t he 4 Cb> cleanrooms however, from 09/05/2024-03/07 /2025, your firm made approximately 41 <bK lots of sterile drug products.

Observation 13 — Drug product containers a nd closures were not clean and steri li

Drug product containers a nd closures were not clean and steri li zed and processed to remove pyrogenic properties to assure that they are su itable for their intended use. Specifically, a) Your firm has not validated the sterilization and/or lb>~> process for the stoppers and vials used by your firm to package sterile drug products. Your firm does L . .J EMPI.OYEE(S) SI GNATURE DATE ISSUED SEE REVERSE Margaret M Annes, cso 9/ 1 8/2025 OF THIS PAGE Katherine M Breed, Veterinary Medical M~WArr..15 cao Officer ~By;M~W....--:s-6 ~~~8-2n25 X 1111:3':'l t PAGE 7 of 15 PAGES

Observation 14 — Each batch of drug product purporting to be sterile and pyrogen-free is

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determ in e confo rm ance to such requ irements. Specifically, your firm is not testing any of your drug products labeled as ster il e for sterility and/or endotoxin prior to re lease/distribution. EMPI.OYEE(S) SIGNATURE DATE ISSUED SEE REVERSE Margaret M Annes, cso 9/ 1 8/2025 OF THIS PAGE Katherine M Breed, Veterinary Medical M~WArr..15 cao Officer ~By;M~W....--:s-6 X ~~~8-2n25 1111:B:1 1 PAGE 8 of 15 PAGES

Observation 15 — There is no written testing program designed to assess th e stability

There is no written testing program designed to assess th e stability characteristi cs of drug products. Specifically , your firm does not have a written stability testi ng program to determine Beyond Use Dates (BUD) placed on all your drug products. Your fi rm has no w ri tten and approved stab il ity protocols and no fi nal written and approved reports. In add ition , your firm has not performed container closu re integrity testing. Your fi rm has no documentation of a stability study having been performed to justify the Beyond Use Dates (BUD) placed on your sterile and no n-ste ri le d ru g products. Examples include: i. Lot #24050745 of Xylazine 10mg/ 1ml Injection had a BUD of 200 days i i. Lot #25080172 of Estradiol Cypionate 2mg/1ml IM Injection had a BUD of 205 days ii i. Lot #25070632 of Reserpine (Aqueous) 2.5mg/1ml IM In jection had a BUD of 187 days.

Observation 16 — Written procedures are not established for the cleaning and maintenance of equipment

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. Specifically, your fi rm has not validated the clean i ng process for equ ipment, beakers, utensils and other items used to make both ster il e and non-steri le drug products. Most eq uipment, beakers and utensils used for sterile and non-sterile d ru g products are fi rst cleaned with store brand liquid dish soap and sponges or scrub brushes. The glass, utensils and some other items used for non-steri le drug products are then placed in to a dish washer using r <bRil> brand dishwash ing detergent. Yo ur firm has no documentation to show that the use of these soaps and detergents are appropriate and su itable for use in clean ing eq uipment used in the preparation of pharmaceutical products. Dies and punches used to make tablets are clean.

Observation 17 — Batch production and control records do not include complete information relati ng

Batch production and control records do not include complete information relati ng to the production and control of each batch . Specifica ll y, your firm's batch records do not include documentation and/or complete documentation of each sig nificant step in the production of drug prod ucts. Fo r example , a) Your firm used a 1 (bl!'4>7 for lot #25050100 of ltraconazole 1% in 10% DMSO Ste~ Ophthalmic Ointment made on 05/07/2025. The batch record states an "r- 4 bX > I 4 !bK > 7' is to be used. b) Your firm does not record the lot number of t he packaging materials such as vials, stoppers , [ , (blr4 i-7 caps, dropper bottles, syringes, and bottles used to package fin ished dosage drug products (sterile an d non-sterile). c) Your firm does no t record in the ba tch record the lot number, brand and size of steril izing fi lter used for any sterile drug.

Observation 18 — Laboratory controls do not include the establishment of scientifically sound and appropriate

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components, drug product containers, closures, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity. Specifically, a) Your firm is incubating media fill vials at a temperature above 1.:1 °c . The temperature documented in the Incubator CbH"> Monitoring Log for media fi ll vials incubated from 01/29/2025-02/26/2025 ranged from 35 .3°C-40° C. T he temperature documented in the Incubator b fft) Monitoring Log for med ia fill vials incubated from 04 /29/2025-05/14/2025 ranged from 34 °C-44.4° C. The temperature documented in the Incubator <bH•> Mon itoring Log for media fi ll vials incubated from 08 /01-14/2025 ranged from 33.4°C-36°C. b) Your firm is incubating I <6)(•> I used for personnel mon itoring for r b)lil)7 at the same temperatures listed above for the media fi l ls. Your firm has no documentation to show.

Observation 19 — Testing and release of drug product for distribution do not in clude

Testing and release of drug product for distribution do not in clude appropriate laboratory determination of satisfactory confo rm ance to the identity and strength of each active i ng redient prior to release. Specifically, your firm does not co nd uct routine testing for potency (assay) for a ll drug products produced by your firm (sterile and non-sterile) ,

Observation 20 — Written procedures are lacking which describe in sufficient detail the receipt, iden

Written procedures are lacking which describe in sufficient detail the receipt, iden ti fication , sampling, testing, approval and rejection of components. Specifically , your firm is using a grocery-store b ran d r (b f(4 >7 water to make sterile and non- sterile drug prod ucts. Your firm does not perform testing (analytical or microbiological) to show the water at least/at mi nimum meets the specifications for r (b)(;f )7 Water, USP. The quality of the water is not appropriate for pharmaceutical use. Non-sterile drug products made with the 4 [ (b)( 7 water inc lu de the gelatin base used to make chewable treats such as lot #25080231 of Pimobendan 1.25mg Chewable Treat and lot #25060237 of Fluoxetine 10mg Chewable Treat. Sterile drug products made wi th r 6lliJ>7 water include the Sodium Carboxymethylcellulose 2.5% Gel used to make Corticotropin (ACTH) 40U/1ml IM Injection. EMPI.OYEE(S) SIGNATURE DATE ISSUED SEE REVERSE Margaret M Annes , cso 9/ 1 8/2025.

Observation 21 — Reports of analysis from component suppliers are accepted in l ie u

Reports of analysis from component suppliers are accepted in l ie u of testing each component for conformity with all appropriate writt en spec ifi cations, without performi ng at least one specific identity test on each component and establishi ng the re li ability of the suppl ier's analyses through appropriate validation of the su pp l ie r's test results at appropriate intervals. Specifically, your firm is prepari ng various sterile and non-steri le drug products from bu lk drug substances. Your fi rm does not perform any testi ng , i ncl uding an identity test, on the incomi ng bu lk d ru g substances or excipients used to make these products.

Observation 22 — Routi ne calibration of automatic, mechanical and electronic equipment is not performed

Routi ne calibration of automatic, mechanical and electronic equipment is not performed according to a written program design ed to assure proper perfor ma n ce. Specifically , yo ur firm is not bracketi ng the ra nge of use w he n ca librating the analytical ba lances used to wei gh ra w mate ri als and/or perform in process weight checks duri ng t he preparation of sterile and non-steri le drug products. Ca l ib rati on by an outside vendor consists of l (b}(4/ J. In a.d~ition , your firm has no documentation to show that t he standard weight set used to perform >H verifica ti on of the ba lances has been cal ibrated. EMP!_OYEE(S) SIGNATURE DATE ISSUED SEE REVERSE Marga r et M Annes , cso 9/ 1 8/2025 OF THIS PAGE Katherine M Breed , Veterinary Medical M~WArr..15 cao Officer ~By;M~W....--:s-6 ~~~8-2n25 X 1111:3':'l t PAGE 14 of 15 PAGES F.

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Petscript Inc’s FDA history

Argus HQ has recorded 1 total FDA action tied to Petscript Inc: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Petscript Inc violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.
What happens after a Form 483 is issued?: The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Petscript Inc

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). September 18, 2025 FDA Form 483 for Petscript Inc — 22 Citations. Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-petscript-inc-2025-09-18-3010282564

MLA

"September 18, 2025 FDA Form 483 for Petscript Inc — 22 Citations." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-petscript-inc-2025-09-18-3010282564.

Chicago

Argus HQ Research. "September 18, 2025 FDA Form 483 for Petscript Inc — 22 Citations." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/483/fda-483-petscript-inc-2025-09-18-3010282564.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_petscript_inc_2025_09_18_3010282564_2025,
  title = {September 18, 2025 FDA Form 483 for Petscript Inc — 22 Citations},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-petscript-inc-2025-09-18-3010282564},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗